Identification

Name
Spirapril
Accession Number
DB01348
Type
Small Molecule
Groups
Approved
Description

Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.

Structure
Thumb
Synonyms
  • Renormax
  • Spirapril
Product Ingredients
IngredientUNIICASInChI Key
Spirapril hydrochlorideOCC25LM89794841-17-5CLDOLNORSLLQDI-OOAIBONUSA-N
International/Other Brands
Renormax
Categories
UNII
96U2K78I3V
CAS number
83647-97-6
Weight
Average: 466.614
Monoisotopic: 466.15961346
Chemical Formula
C22H30N2O5S2
InChI Key
HRWCVUIFMSZDJS-SZMVWBNQSA-N
InChI
InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
IUPAC Name
(8S)-7-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]@H](C)C(=O)N1CC2(C[[email protected]]1C(O)=O)SCCS2

Pharmacology

Indication

Spirapril is an ACE inhibitor class drug used to treat hypertension.

Structured Indications
Not Available
Pharmacodynamics

Spirapril is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, spirapril decreases angiotensin II which is a vasoconstrictor and inducer of aldosterone. So by inhibiting the enzymes, aldosterone secreation is decreased (so less sodium is reabsorbed) and there is a decrease in vasoconstriction. Combined, this leades to a decrease in blood pressure.

Mechanism of action

Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Bioavailability is 50% following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Converted to spiraprilat following oral administration.

Route of elimination
Not Available
Half life

30 to 35 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Spirapril Action PathwayDrug action
Spirapril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Spirapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Spirapril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Spirapril.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Spirapril is combined with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Spirapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Spirapril is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Spirapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Spirapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Spirapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Spirapril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Spirapril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Spirapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Spirapril.Approved, Withdrawn
AmbrisentanSpirapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Spirapril.Experimental, Investigational
AmifostineSpirapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Spirapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Spirapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Spirapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Spirapril.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Spirapril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Spirapril.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Spirapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Spirapril.Approved, Illicit
AndrographolideThe risk or severity of adverse effects can be increased when Spirapril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Spirapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Spirapril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Spirapril is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Spirapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Spirapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Spirapril.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Spirapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Spirapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Spirapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Azapropazone.Withdrawn
AzathioprineSpirapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Spirapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Spirapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Spirapril is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Spirapril.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Spirapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Spirapril is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Spirapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Spirapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Spirapril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Spirapril is combined with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Spirapril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Spirapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Spirapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Spirapril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Spirapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Spirapril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Spirapril.Approved
BoceprevirThe serum concentration of Spirapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanBosentan may increase the hypotensive activities of Spirapril.Approved, Investigational
BQ-123Spirapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Spirapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Spirapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Spirapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Spirapril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Spirapril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Bumadizone.Experimental
BumetanideBumetanide may increase the hypotensive activities of Spirapril.Approved
BupranololSpirapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Spirapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Spirapril.Experimental
CafedrineSpirapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Spirapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Spirapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Spirapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Spirapril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Spirapril.Approved
CarbamazepineThe metabolism of Spirapril can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Spirapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Spirapril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Spirapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Spirapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Celecoxib.Approved, Investigational
CeliprololSpirapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Spirapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Spirapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Spirapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Spirapril.Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Spirapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Spirapril is combined with Choline magnesium trisalicylate.Approved
CicletanineSpirapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Spirapril.Approved
CiprofloxacinSpirapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Spirapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Spirapril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Spirapril.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Spirapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Spirapril is combined with Clonixin.Approved
CloranololSpirapril may increase the hypotensive activities of Cloranolol.Experimental
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Spirapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Spirapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Spirapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Spirapril.Approved
CyclopenthiazideSpirapril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Spirapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Spirapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Spirapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Spirapril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Spirapril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Spirapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Spirapril.Approved, Investigational
DelaprilSpirapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Spirapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Spirapril.Investigational
DeserpidineSpirapril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Spirapril.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Spirapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Spirapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Spirapril.Approved, Investigational
diethylnorspermineSpirapril may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Spirapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Spirapril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Spirapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Spirapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Spirapril.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Spirapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Spirapril.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Spirapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Spirapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Spirapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Spirapril.Approved
DrospirenoneSpirapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Spirapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Spirapril.Approved
E-6201The risk or severity of adverse effects can be increased when Spirapril is combined with E-6201.Investigational
EfonidipineSpirapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Spirapril.Approved, Vet Approved
EnalaprilatSpirapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Spirapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Spirapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Spirapril.Approved
EpanololSpirapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Spirapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Spirapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Spirapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Spirapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Spirapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Spirapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Spirapril.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Spirapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Spirapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Spirapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Spirapril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Spirapril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Spirapril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Spirapril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Spirapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Spirapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Spirapril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Spirapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Spirapril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Spirapril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Spirapril is combined with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Spirapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Spirapril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Spirapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Spirapril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Feprazone.Experimental
Ferulic acidSpirapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Spirapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Spirapril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Spirapril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Spirapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Spirapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Spirapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Spirapril.Approved, Vet Approved
GarlicThe serum concentration of Spirapril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Spirapril.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Spirapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Spirapril.Approved
GuanazodineSpirapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Spirapril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Spirapril.Approved, Investigational
GuanoclorSpirapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzSpirapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanSpirapril may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Spirapril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Spirapril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Spirapril.Approved, Investigational
HexamethoniumSpirapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Spirapril.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Spirapril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Spirapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Spirapril.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Spirapril.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Spirapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Spirapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Spirapril.Approved
IloprostIloprost may increase the hypotensive activities of Spirapril.Approved, Investigational
ImidaprilSpirapril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Spirapril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Spirapril.Approved
IndapamideIndapamide may increase the hypotensive activities of Spirapril.Approved
IndenololSpirapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Spirapril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Spirapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Spirapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Spirapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Spirapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Spirapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Spirapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Spirapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Spirapril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Spirapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Spirapril.Approved
LacidipineSpirapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Spirapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Spirapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Spirapril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Spirapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Spirapril.Approved
LinsidomineSpirapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Spirapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Spirapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Spirapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Spirapril.Experimental
LofexidineSpirapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Spirapril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Spirapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Spirapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Lumiracoxib.Approved, Investigational
MacitentanSpirapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Spirapril is combined with Magnesium salicylate.Approved
ManidipineSpirapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Spirapril is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Spirapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Spirapril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Spirapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Spirapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Spirapril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Spirapril.Experimental
MethoserpidineSpirapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Spirapril.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Spirapril.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Spirapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Spirapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Spirapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Spirapril.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Spirapril.Approved
MetolazoneMetolazone may increase the hypotensive activities of Spirapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Spirapril.Approved, Investigational
MetyrosineSpirapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilSpirapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Spirapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Spirapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Spirapril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Spirapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Spirapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Spirapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Spirapril.Approved
MoexiprilMoexipril may increase the hypotensive activities of Spirapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Spirapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Spirapril.Approved, Investigational
MuzolimineSpirapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Spirapril.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Spirapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Spirapril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Spirapril is combined with Naftifine.Approved
NaftopidilSpirapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Spirapril is combined with Naproxen.Approved, Vet Approved
NebivololSpirapril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Spirapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Spirapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Spirapril.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Spirapril.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Spirapril is combined with Niflumic Acid.Approved
NiguldipineSpirapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineSpirapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Spirapril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Spirapril.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Spirapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Spirapril.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Spirapril.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Spirapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Spirapril.Approved
ObinutuzumabSpirapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Spirapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spirapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Spirapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Spirapril is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Spirapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Spirapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Spirapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxaprozin.Approved
OxprenololSpirapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Spirapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Spirapril.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Spirapril is combined with Parthenolide.Investigational
PenbutololSpirapril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Spirapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Spirapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Spirapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Spirapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Spirapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Spirapril.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Spirapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Spirapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Spirapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Spirapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Spirapril.Approved
PinacidilPinacidil may increase the hypotensive activities of Spirapril.Withdrawn
PindololPindolol may increase the hypotensive activities of Spirapril.Approved
PiretanidePiretanide may increase the hypotensive activities of Spirapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Spirapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Spirapril.Withdrawn
Platelet Activating FactorSpirapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Spirapril.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Spirapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Spirapril is combined with Pregabalin.Approved, Illicit, Investigational
ProcarbazineProcarbazine may increase the hypotensive activities of Spirapril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Spirapril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Spirapril is combined with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Spirapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Spirapril.Approved
PTC299The risk or severity of adverse effects can be increased when Spirapril is combined with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Spirapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Spirapril.Approved
QuinineQuinine may increase the hypotensive activities of Spirapril.Approved
RamiprilRamipril may increase the hypotensive activities of Spirapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Spirapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Spirapril.Approved
RescinnamineSpirapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Spirapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Spirapril is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Spirapril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Spirapril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Spirapril.Approved
RituximabSpirapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Rofecoxib.Investigational, Withdrawn
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Spirapril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Spirapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Spirapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Spirapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Spirapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Spirapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Spirapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Spirapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Spirapril.Approved
SelegilineSelegiline may increase the hypotensive activities of Spirapril.Approved, Investigational, Vet Approved
SelexipagSpirapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Spirapril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Spirapril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Spirapril is combined with Serrapeptase.Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Spirapril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Spirapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Spirapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Spirapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Spirapril.Approved, Investigational
SitaxentanSpirapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Spirapril is combined with Sodium aurothiomalate.Approved
Sodium phosphateSpirapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when Spirapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Spirapril can be increased when combined with St. John's Wort.Investigational, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Spirapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Spirapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Spirapril.Approved, Investigational
TalinololSpirapril may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Spirapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Spirapril.Approved, Investigational
TemocaprilSpirapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Spirapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Spirapril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Spirapril is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Spirapril is combined with Teriflunomide.Approved
TerlipressinSpirapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineSpirapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineSpirapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Spirapril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Spirapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Tiaprofenic acid.Approved
TiboloneSpirapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenSpirapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Spirapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Spirapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Spirapril.Approved
TipranavirThe serum concentration of Spirapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Spirapril.Approved
TolazolineTolazoline may increase the hypotensive activities of Spirapril.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolmetin.Approved
TolonidineSpirapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Spirapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Spirapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Spirapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Spirapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Spirapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Spirapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Spirapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Spirapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Spirapril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Spirapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Spirapril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Spirapril is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Spirapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Spirapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Spirapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Spirapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Spirapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Spirapril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Spirapril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Spirapril.Approved, Investigational
UnoprostoneSpirapril may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Spirapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Spirapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Spirapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Spirapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Spirapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Spirapril.Approved, Investigational
VincamineSpirapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineSpirapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideSpirapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineSpirapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Spirapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Spirapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Spirapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilSpirapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Spirapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or iron supplements within 2 hours of taking this medication.
  • Herbs that may attenuate the antihypertensive effect of spirapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of spirapril.
  • Spirapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

References

General References
  1. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161]
  2. Noble S, Sorkin EM: Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. [PubMed:7601014]
  3. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157]
  4. Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G: Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. Scand J Urol Nephrol. 1999 Feb;33(1):57-62. [PubMed:10100366]
External Links
Human Metabolome Database
HMDB15438
PubChem Compound
5311447
PubChem Substance
46506126
ChemSpider
4470933
BindingDB
50017124
ChEBI
135756
ChEMBL
CHEMBL431
Therapeutic Targets Database
DAP000911
PharmGKB
PA164776913
Wikipedia
Spirapril
ATC Codes
C09AA11 — Spirapril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0293 mg/mLALOGPS
logP1.79ALOGPS
logP1.6ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.62ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity121.94 m3·mol-1ChemAxon
Polarizability48.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5287
Blood Brain Barrier-0.9614
Caco-2 permeable-0.83
P-glycoprotein substrateSubstrate0.8223
P-glycoprotein inhibitor INon-inhibitor0.6938
P-glycoprotein inhibitor IINon-inhibitor0.7426
Renal organic cation transporterNon-inhibitor0.8836
CYP450 2C9 substrateNon-substrate0.833
CYP450 2D6 substrateNon-substrate0.8553
CYP450 3A4 substrateNon-substrate0.5658
CYP450 1A2 substrateNon-inhibitor0.8439
CYP450 2C9 inhibitorNon-inhibitor0.7259
CYP450 2D6 inhibitorNon-inhibitor0.8813
CYP450 2C19 inhibitorNon-inhibitor0.5956
CYP450 3A4 inhibitorInhibitor0.5073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6331
Ames testNon AMES toxic0.8764
CarcinogenicityNon-carcinogens0.908
BiodegradationNot ready biodegradable0.9115
Rat acute toxicity2.2396 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.5579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
N-acyl-L-alpha-amino acids / Alpha amino acid esters / Alpha amino acid amides / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Fatty acid esters / Dithioketals / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives
show 12 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
  2. Maul B, Krause W, Pankow K, Becker M, Gembardt F, Alenina N, Walther T, Bader M, Siems WE: Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81. [PubMed:16126915]
  3. Hermida RC, Ayala DE, Fontao MJ, Mojon A, Alonso I, Fernandez JR: Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int. 2010 May;27(3):560-74. doi: 10.3109/07420528.2010.485411. [PubMed:20524801]
  4. Arend U, Albrecht S, Meisel E, Schmidt J: [Influence of ACE inhibitor spirapril on left ventricular hypertrophy]. Fortschr Med Orig. 2002 Dec 5;120(4):147-50. [PubMed:12613273]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 30, 2007 12:15 / Updated on December 01, 2017 17:23